CAMBRIDGE, Mass., November 22, 2021 — Korro Bio, Inc. , an RNA editing company focused on the discovery and development of novel genetic medicines, today announced that Ram Aiyar, Ph.D., MBA, Chief Executive Officer, will participate in two upcoming virtual healthcare investor conferences, as
CAMBRIDGE, Mass., August 31, 2021 — Korro Bio, Inc. , an RNA editing company focused on the discovery and development of novel genetic medicines, today announced that Ram Aiyar, Ph.D., MBA, chief executive officer, will present at the 2021 Wells Fargo Healthcare Conference and participate in a
CAMBRIDGE, Mass., May 24, 2021 — Korro Bio, Inc. , an RNA editing company focused on the discovery and development of novel genetic medicines, today announced that Ram Aiyar, Ph.D., MBA, chief executive officer, will present at the 2021 Jefferies Virtual Healthcare Conference on June 4, 2021, at
CAMBRIDGE, Mass., May 11, 2021 — Korro Bio, Inc ., an RNA editing company focused on the discovery and development of novel genetic medicines, today announced the appointment of Vineet Agarwal as Chief Financial Officer. He joins Korro from J.P. Morgan Chase & Co., where he most recently served as
CAMBRIDGE, Mass., April 1, 2021 — Korro Bio, Inc ., an RNA editing company focused on the discovery and development of novel genetic medicines, today announced the appointment of Howard Stern, M.D., Ph.D. as Chief Scientific Officer. Dr. Stern is a seasoned biotechnology executive with extensive
CAMBRIDGE, Mass., March 5, 2021 — Korro Bio, Inc. , a biotechnology company developing single-base RNA editing therapies, today announced that Ram Aiyar, Ph.D., MBA, chief executive officer, will present at the Barclays Global Healthcare Conference and the WuXi Healthcare Forum this month. Dr.
CAMBRIDGE, Mass., Jan. 7, 2021 – Korro Bio, Inc. , a biotechnology company developing single-base RNA editing therapies, today announced that Ram Aiyar, Ph.D., MBA, chief executive officer, will present an update on Korro’s progress at the 39 th Annual J.P. Morgan Healthcare Conference.
Dr. Aiyar brings nearly two decades of diverse experience across biotech and pharma to prepare for Korro’s next stage of growth CAMBRIDGE, Mass., November 10, 2020 – Korro Bio, Inc. , a biotechnology company developing single-base RNA editing therapies, today announced the appointment of Ram Aiyar,
Korro Bio strengthens board of directors with appointment of industry leader, Omar Khwaja, M.D., Ph.D. CAMBRIDGE, Mass., October 1, 2020 – Korro Bio, Inc ., a biotechnology company developing single-base RNA editing therapies, today announced the appointment of Omar Khwaja, M.D., Ph.D.
CAMBRIDGE, Mass., September 10, 2020 – Korro Bio, Inc. today announced a $91.5 million Series A financing to advance its novel platform for precise, single-base, RNA editing to modulate protein function for therapeutic applications. This financing enables Korro to advance its lead program to IND
